Back to Journals » Transplant Research and Risk Management » Volume 9

Risk factors, diagnosis, and management of posttransplant lymphoproliferative disorder: improving patient outcomes with a multidisciplinary treatment approach

Authors Ligeti K, Müller LP, Müller-Tidow C, Weber T

Received 7 April 2016

Accepted for publication 22 July 2016

Published 27 January 2017 Volume 2017:9 Pages 1—14

DOI https://doi.org/10.2147/TRRM.S84744

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Professor Qing Yi


Kinga Ligeti, Lutz P Müller, Carsten Müller-Tidow, Thomas Weber

Department of Hematology and Oncology, University Hospital Halle (Saale) and Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany


Abstract: Posttransplant lymphoproliferative disease (PTLD) is a major complication after solid organ transplantation and allogeneic hematopoietic stem cell transplantation. The spectrum of PTLD ranges from benign hyperplasia to malignant lymphoma, representing one of the most relevant malignancies in these patients. Most PTLDs are driven by latent Epstein–Barr virus infections. The backbone of treatment is reduction of immunosuppression. Further treatment depends on the type of PTLD and the type of transplantation. A multidisciplinary approach involving transplant team, hematologists, and other disciplines is crucial for the diagnosis and treatment of PTLD and for concurrent preservation of the transplant function. In this study, known pathomechanisms, risk factors, preemptive management, and especially emerging treatment algorithms in PTLD were reviewed.

Keywords: lymphoproliferative disease, Epstein-Barr virus, management, rituximab, ­preemptive therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]